Redmile Group, LLC Tricida, Inc. Call Options Transaction History
Redmile Group, LLC
- $822 Million
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TCDA
# of Institutions
4Shares Held
30KCall Options Held
124KPut Options Held
46.5KAbout Tricida, Inc.
- Ticker TCDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,668,900
- Market Cap $557K
- Description
- Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...